文献速递消化、代谢与肾脏急症

双激素仿生胰腺治疗1型糖尿病的多中心随机试验

Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
PubMed 文献 · N Engl J Med · 2022-01-01
一句话结论13周多中心随机试验显示,仿生胰腺较标准治疗更大幅度降低1型糖尿病患者的糖化血红蛋白(7.9%→7.3% vs 7.7%→7.7%,校正差异-0.5个百分点,95%CI -0.6至-0.3,P<0.001)。

该13周多中心随机试验纳入≥6岁1型糖尿病患者,按2:1随机分配至仿生胰腺组(219例,使用门冬胰岛素或赖脯胰岛素)或标准治疗组(107例,任何胰岛素给药方法联合非盲法实时持续葡萄糖监测)。主要终点为13周时糖化血红蛋白水平,仿生胰腺组从7.9%降至7.3%,标准治疗组维持7.7%(校正差异-0.5个百分点,95%CI -0.6至-0.3,P<0.001)。关键次要终点为持续葡萄糖监测显示血糖低于54 mg/dL的时间百分比,两组无显著差异(校正差异0.0个百分点,95%CI -0.1至0.04,非劣效性P<0.001)。严重低血糖发生率仿生胰腺组为17.7事件/100参与者年,标准治疗组为10.8事件/100参与者年(P=0.39),两组均无糖尿病酮症酸中毒发生。

要点

  • 仿生胰腺仅根据体重初始化,自主决定并输注所有胰岛素剂量,进餐时仅需宣告进餐而无需计算碳水化合物。
  • 13周时糖化血红蛋白仿生胰腺组从7.9%降至7.3%,标准治疗组维持7.7%,校正差异-0.5个百分点(95%CI -0.6至-0.3,P<0.001)。
  • 持续葡萄糖监测血糖低于54 mg/dL的时间百分比两组无显著差异(校正差异0.0个百分点,95%CI -0.1至0.04,非劣效性P<0.001,预设非劣效界值1个百分点)。
  • 严重低血糖发生率仿生胰腺组17.7事件/100参与者年 vs 标准治疗组10.8事件/100参与者年(P=0.39)。
  • 两组均无糖尿病酮症酸中毒发生。

适用人群与场景

  • 年龄至少6岁的1型糖尿病患者,实际纳入年龄6至79岁。
  • 多中心住院外场景下使用,试验为期13周。

诊断标准与关键阈值

  • 主要终点为13周时糖化血红蛋白水平。
  • 关键次要终点为持续葡萄糖监测评估的血糖低于54 mg/dL的时间百分比,预设非劣效性界值为1个百分点。

处置流程与药物剂量

  • 仿生胰腺组使用门冬胰岛素或赖脯胰岛素,仅根据体重初始化,系统自主决定并输注所有胰岛素剂量,进餐时仅宣告进餐而不计算碳水化合物。
  • 标准治疗组采用任何胰岛素给药方法联合非盲法实时持续葡萄糖监测。

研究设计与关键结果

  • 研究类型:13周多中心随机试验,按2:1比例随机分配。
  • 样本量:仿生胰腺组219例,标准治疗组107例,共326例,年龄6至79岁。
  • 主要终点:糖化血红蛋白仿生胰腺组从7.9%降至7.3%,标准治疗组维持7.7%(两时间点均为7.7%),13周时平均校正差异-0.5个百分点(95%CI -0.6至-0.3,P<0.001)。
  • 关键次要终点:持续葡萄糖监测血糖低于54 mg/dL的时间百分比两组无显著差异(13周校正差异0.0个百分点,95%CI -0.1至0.04,非劣效性P<0.001)。
  • 安全性:严重低血糖发生率仿生胰腺组17.7事件/100参与者年 vs 标准治疗组10.8事件/100参与者年(P=0.39);两组均无糖尿病酮症酸中毒发生。

证据类型、等级与局限

  • 证据类型:多中心随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于≥6岁1型糖尿病患者,仿生胰腺治疗可较标准治疗更大幅度降低糖化血红蛋白(校正差异-0.5个百分点,95%CI -0.6至-0.3),且不增加血糖低于54 mg/dL的时间百分比。
  • 仿生胰腺无需碳水化合物计算和个体化胰岛素方案初始化,仅根据体重初始化,可能简化胰岛素管理。
  • 严重低血糖发生率两组无显著差异(P=0.39),但仿生胰腺组数值上较高(17.7 vs 10.8事件/100参与者年)。

指南或共识出处

  • N Engl J Med: Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes (NCT04200313)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Currently available semiautomated insulin-delivery systems require individualized insulin regimens for the initialization of therapy and meal doses based on carbohydrate counting for routine operation. In contrast, the bionic pancreas is initialized only on the basis of body weight, makes all dose decisions and delivers insulin autonomously, and uses meal announcements without carbohydrate counting.

METHODS: In this 13-week, multicenter, randomized trial, we randomly assigned in a 2:1 ratio persons at least 6 years of age with type 1 diabetes either to receive bionic pancreas treatment with insulin aspart or insulin lispro or to receive standard care (defined as any insulin-delivery method with unblinded, real-time continuous glucose monitoring). The primary outcome was the glycated hemoglobin level at 13 weeks. The key secondary outcome was the percentage of time that the glucose level as assessed by continuous glucose monitoring was below 54 mg per deciliter; the prespecified noninferiority limit for this outcome was 1 percentage point. Safety was also assessed.

RESULTS: A total of 219 participants 6 to 79 years of age were assigned to the bionic-pancreas group, and 107 to the standard-care group. The glycated hemoglobin level decreased from 7.9% to 7.3% in the bionic-pancreas group and did not change (was at 7.7% at both time points) in the standard-care group (mean adjusted difference at 13 weeks, -0.5 percentage points; 95% confidence interval [CI], -0.6 to -0.3; P<0.001). The percentage of time that the glucose level as assessed by continuous glucose monitoring was below 54 mg per deciliter did not differ significantly between the two groups (13-week adjusted difference, 0.0 percentage points; 95% CI, -0.1 to 0.04; P<0.001 for noninferiority). The rate of severe hypoglycemia was 17.7 events per 100 participant-years in the bionic-pancreas group and 10.8 events per 100 participant-years in the standard-care group (P = 0.39). No episodes of diabetic ketoacidosis occurred in either group.

CONCLUSIONS: In this 13-week, randomized trial involving adults and children with type 1 diabetes, use of a bionic pancreas was associated with a greater reduction than standard care in the glycated hemoglobin level. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov number, NCT04200313.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Russell SJ, Beck RW, Damiano ER, et al. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. N Engl J Med. 2022. PMID: 36170500. doi:10.1056/NEJMoa2205225

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。